ReviewJournal of clinical medicine2022
Clinical Utilities of Anti-Müllerian Hormone.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- The role of anti-Müllerian hormone as a therapeutic agent to preserve the ovarian follicle pool during chemotherapy.Journal of assisted reproduction and genetics · 2026Review
- Relationship between anti-Müllerian hormone concentration in the peripheral blood of women and aneuploid pregnancy.BMC pregnancy and childbirth · 2026Article
- Pilot Study on the Effects of First-Line Antituberculosis Drugs and Their Combinations on Selected Reproductive Endpoints in Female Rats.Life (Basel, Switzerland) · 2026Article
- Protective Effects of Adenosine Triphosphate and Flunarizine on Erlotinib-Induced Ovarian Damage: An Experimental Study.Life (Basel, Switzerland) · 2026Article
- Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss ofFrontiers in endocrinology · 2026Article
- Diagnostic accuracy of AMH for primary ovarian insufficiency/premature ovarian failure: a real-world cohort study.Frontiers in endocrinology · 2026Article
- Review
- [Female reproductive function -after radioiodine therapy for differentiated thyroid carcinoma].Problemy endokrinologii · 2025Article
- The role of anti-Müllerian hormone: insights into ovarian reserve, primary ovarian insufficiency, and menopause prediction.Endocrine · 2025Review
- AMH regulates granulosa cell function via ESR2/ p38-MAPK signaling pathway in sheep.Communications biology · 2025Article
- Clinical utility of anti-Müllerian hormone in female children and adolescents.Hormones (Athens, Greece) · 2025Review
- Effect of COVID-19 inactivated vaccine on anti-Müllerian hormone in Chinese women: a retrospective cohort study.Frontiers in endocrinology · 2025Article
- New potential in the treatment of moderate to severe intrauterine adhesions: influencing factors for menstrual improvement.Frontiers in reproductive health · 2025Review
- Article
- Article
- Establishing a Gold Standard for Quantitative Menstrual Cycle Monitoring.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anti-Müllerian hormone (AMH) plays an essential role in sex determination in early embryonic development. Through a series of sequential steps that follows inheriting an XY chromosome, Sertoli cell differentiation upregulates the expression of AMH-suppressing Müllerian duct development and maintains the AMH at a high level until puberty. In females, the AMH is produced by granulosa cells of follicles beginning in the second half of fetal life and continues through adulthood, with a steady decline through the reproductive years and severe decline at menopause, until levels eventually become undetectable. The AMH is essential for the regulation of follicular maturation via the recruitment of primordial follicles throughout folliculogenesis. AMH serum concentration in women strongly correlates with ovarian reserve quantity and reflects ovulation potential. Because the AMH is expressed almost exclusively by growing follicles before FSH-dependent selection, it commonly serves as a marker for ovarian function in various clinical situations, including in the diagnosis and pathogenesis of polycystic ovarian syndrome, artificial reproductive technology, and predictions of menopause or premature ovarian failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.